Abstract
Alzheimer’s disease (AD) is a clinically, anatomically and biologically heterogeneous disorder encompassing a wide spectrum of cognitive profiles, ranging from the typical amnestic syndrome to visuospatial changes in posterior cortical atrophy, language deficits in primary progressive aphasia and behavioural/executive dysfunctions in anterior variants. With the emergence of functional imaging and neural network analysis using graph theory for instance, some authors have hypothesized that this phenotypic variability is produced by the differential involvement of large-scale neural networks – a model called ‘molecular nexopathy’. At the moment, however, the hypothesized mechanisms underlying AD’s divergent network degeneration remain speculative and mostly involve selective premorbid network vulnerability. Herein we present an overview of AD’s clinicoanatomical variability, outline functional imaging and graph theory contributions to our understanding of the disease and discuss ongoing debates regarding the biological roots of its heterogeneity. We finally discuss the clinical promises of statistical signal processing disciplines (graph theory and information theory) in predicting the trajectory of AD variants. This paper aims to raise awareness about AD clinicoanatomical heterogeneity and outline how statistical signal processing methods could lead to a better understanding, diagnosis and treatment of AD variants in the future.
Keywords: Alzheimer’s disease, frontal AD, functional connectivity, heterogeneity, logopenic aphasia, posterior cortical atrophy, selective network vulnerability.
Current Alzheimer Research
Title:Untangling Alzheimer’s Disease Clinicoanatomical Heterogeneity Through Selective Network Vulnerability – An Effort to Understand a Complex Disease
Volume: 13 Issue: 5
Author(s): David Bergeron, Reda Bensaïdane and Robert Laforce
Affiliation:
Keywords: Alzheimer’s disease, frontal AD, functional connectivity, heterogeneity, logopenic aphasia, posterior cortical atrophy, selective network vulnerability.
Abstract: Alzheimer’s disease (AD) is a clinically, anatomically and biologically heterogeneous disorder encompassing a wide spectrum of cognitive profiles, ranging from the typical amnestic syndrome to visuospatial changes in posterior cortical atrophy, language deficits in primary progressive aphasia and behavioural/executive dysfunctions in anterior variants. With the emergence of functional imaging and neural network analysis using graph theory for instance, some authors have hypothesized that this phenotypic variability is produced by the differential involvement of large-scale neural networks – a model called ‘molecular nexopathy’. At the moment, however, the hypothesized mechanisms underlying AD’s divergent network degeneration remain speculative and mostly involve selective premorbid network vulnerability. Herein we present an overview of AD’s clinicoanatomical variability, outline functional imaging and graph theory contributions to our understanding of the disease and discuss ongoing debates regarding the biological roots of its heterogeneity. We finally discuss the clinical promises of statistical signal processing disciplines (graph theory and information theory) in predicting the trajectory of AD variants. This paper aims to raise awareness about AD clinicoanatomical heterogeneity and outline how statistical signal processing methods could lead to a better understanding, diagnosis and treatment of AD variants in the future.
Export Options
About this article
Cite this article as:
Bergeron David, Bensaïdane Reda and Laforce Robert, Untangling Alzheimer’s Disease Clinicoanatomical Heterogeneity Through Selective Network Vulnerability – An Effort to Understand a Complex Disease, Current Alzheimer Research 2016; 13 (5) . https://dx.doi.org/10.2174/1567205013666151116125155
DOI https://dx.doi.org/10.2174/1567205013666151116125155 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Alzheimer Disease and Type 2 Diabetes Mellitus: The Link to Tyrosine Hydroxylase and Probable Nutritional Strategies
CNS & Neurological Disorders - Drug Targets Meet Our Editorial Board Member
Current Neuropharmacology In Silico Binding Mode Proposed for Flavonoid Ligands of Tau Protein with Interest in Alzheimer's Disease
Current Bioactive Compounds Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Is there a Rational Approach for Increasing Drug Specificity? Considerations on CNS Target Choice and Validation
Recent Patents on CNS Drug Discovery (Discontinued) 5-HT1 Receptors
Current Drug Targets - CNS & Neurological Disorders Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder
CNS & Neurological Disorders - Drug Targets Biological Therapies: Effects of Proinflammatory Pathways and their Inhibition on the Myocardium of Rheumatoid Athritis Patients
Current Medicinal Chemistry Statins May Prevent Atherosclerotic Disease in OSA Patients without Co-Morbidities?
Current Vascular Pharmacology Genomics and Pharmacogenomics of Brain Disorders
Current Pharmaceutical Biotechnology Drug-Delivery Systems of Green Tea Catechins for Improved Stability and Bioavailability
Current Medicinal Chemistry Neuroprotective Therapy for HIV Dementia
Current HIV Research Selective Targeting of Muscarinic Receptors: Novel Therapeutic Approaches for Psychotic Disorders
Current Neuropharmacology Targeting RGD Recognizing Integrins: Drug Development, Biomaterial Research, Tumor Imaging and Targeting
Current Pharmaceutical Design Nuclear Medicine: Proof of Principle for Targeted Drugs in Diagnosis and Therapy
Current Pharmaceutical Design Anticoagulant Therapy in Pregnant Patients with Metabolic Syndrome: A Review
Current Pharmaceutical Biotechnology Facile Utilisation of Aldehyde Bisulfite Adducts: Synthesis of (E)-1,2- Diphenylethenes
Letters in Organic Chemistry Novel Insights for Multiple Sclerosis and Demyelinating Disorders with Apoptosis, Autophagy, FoxO, and mTOR
Current Neurovascular Research Development of New Drugs that Act Through Membrane Receptors and Involve an Action of Inverse Agonism
Recent Patents on CNS Drug Discovery (Discontinued) Cardiovascular Disease Risk Among the Poor and Homeless – What We Know So Far
Current Cardiology Reviews